The results of a clinical phase III data demonstrate the effectiveness of the use of poloxamer of marbocyl as post-exposure prevention of influenza. The results of a study published in The New England Journal of Medicine.
The study BLOCKSTONE participated 545 patients with influenza and members of their families (752 people). Depending on the group participants received poloxamer or a placebo. According to the data obtained, the greatest efficacy as a prophylactic agent was observed among people with high risk of complications of influenza and children under 12 years and persons who had not been immunized against influenza.
The study authors emphasize that in the group of the use of poloxamer, the frequency of infection in family members was significantly lower. The incidence of adverse events in the active treatment groups and placebo were comparable.
Blackwire karboksil — the first in its class medication for a single ingestion, with a new mechanism of action: the drug inhibits cap-dependent endonuclease — specific enzyme required for replication of the virus. The active ingredient of the drug upon contact with biological media transformered to the active metabolite that prevents the synthesis of the matrix RNA of the virus, for which there is synthesis of viral protein necessary for the formation of viral particles. The development of a drug deal and Shionogi Roche, while Roche owns the license rights for the drug worldwide, except Japan and Taiwan.